TheProfitWatch

EDIT - Editas Medicine, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
2.42 0.02 (1.03%) 0.0 (0.0%) -0.01 (-0.41%) -0.02 (-0.61%) 0.03 (1.24%) 0.0 (0.2%) 0.03 (1.13%) 0.02 (0.72%)

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.63
Diluted EPS:
-0.63
Basic P/E:
-3.881
Diluted P/E:
-3.881
RSI(14) 1m:
61.01
VWAP:
2.45
RVol:

Events

Period Kind Movement Occurred At

Related News